Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | MMP1 | P03956 | 2/20 | 0.72 |
| ▸ | MMP7 | P09237 | 2/20 | 0.72 |
| ▸ | MMP8 | P22894 | 2/20 | 0.72 |
| ▸ | MMP12 | P39900 | 2/20 | 0.72 |
| ▸ | MMP13 | P45452 | 2/20 | 0.72 |
| ▸ | BMP1 | P13497 | 6/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.55 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324195 | 0.91 | SMN1; SMN2 (0.65) | SMN1; SMN2MMP1MMP7MMP8MMP12 | |
| SCHEMBL4928380 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2MMP1MMP7MMP8MMP12 | |
| SCHEMBL6321588 | 0.85 | TAS2R14 (0.69) | SMN1; SMN2MMP1MMP7MMP8MMP12 | |
| SCHEMBL13979922 | 0.85 | CNR2 (0.61) | SMN1; SMN2MMP1MMP7MMP8MMP12 | |
| SCHEMBL17230532 | 0.83 | BMP1 (0.55) | SMN1; SMN2MMP1MMP7MMP8MMP12 | |
| SCHEMBL3615482 | 0.83 | BMP1 (0.55) | SMN1; SMN2MMP1MMP7MMP8MMP12 | |
| SCHEMBL14229338 | 0.82 | TAS2R14 (0.62) | SMN1; SMN2MMP1MMP7MMP8MMP12 | |
| SCHEMBL4204765 | 0.80 | LMNA (0.76) | SMN1; SMN2MMP1MMP7MMP8MMP12 | |
| SCHEMBL218536 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2MMP1MMP7MMP8MMP12 | |
| SCHEMBL10385428 | 0.79 | BMP1 (0.51) | SMN1; SMN2MMP1MMP7MMP8MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-20040059138-A1 | Dihydropyrancarboxamides and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059138-A1 | Dihydropyrancarboxamides and uses thereof | CCNA1, DPYD, DHFR | SMN1; SMN2 3326/4885MMP1 1699/4885MMP7 2476/4885 |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | CCNA1, DPYD, DHFR | SMN1; SMN2 2510/4885MMP1 2095/4885MMP7 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.